| 6.8 0.29 (4.45%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 8.63 | 1-year : | 10.08 |
| Resists | First : | 7.38 | Second : | 8.63 |
| Pivot price | 6.26 |
|||
| Supports | First : | 5.59 | Second : | 4.48 |
| MAs | MA(5) : | 6.61 |
MA(20) : | 5.93 |
| MA(100) : | 3.85 |
MA(250) : | 3.45 |
|
| MACD | MACD : | 0.5 |
Signal : | 0.5 |
| %K %D | K(14,3) : | 67.9  |
D(3) : | 69.8 |
| RSI | RSI(14): 60.1 |
|||
| 52-week | High : | 7.38 | Low : | 2.24 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ABSI ] has closed below upper band by 28.8%. Bollinger Bands are 87.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 10 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 7.1 - 7.13 | 7.13 - 7.15 |
| Low: | 6.3 - 6.33 | 6.33 - 6.35 |
| Close: | 6.75 - 6.8 | 6.8 - 6.84 |
Absci Corporation operates as a biopharmaceutical company primarily focused on discovering novel drug targets and developing new therapeutic compounds. Leveraging its distinctive integrated drug creation platform, the firm generates potential biologic medicines and essential cell lines for manufacturing, which it provides to its collaborators, predominantly within the United States. This advanced platform is instrumental in facilitating the development of biologics by meticulously integrating the traditionally separate stages of drug discovery and cell line engineering into one streamlined process. Absci Corporation was founded in 2011 and is based in Vancouver, Washington.
Fri, 12 Jun 2026
Absci Insiders Land Bargain With Gains Of US$1.4m - Moomoo
Thu, 11 Jun 2026
Absci (ABSI) director Karen McGinnis granted RSUs and stock options - Stock Titan
Wed, 10 Jun 2026
Absci Corporation (ABSI) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Slideshow - Seeking Alpha
Tue, 09 Jun 2026
Absci Corporation: A Big Binary Approaching In Alopecia (NASDAQ:ABSI) - Seeking Alpha
Mon, 08 Jun 2026
Absci (NASDAQ: ABSI) director Mary Szela awarded RSUs and stock options - Stock Titan
Mon, 08 Jun 2026
Absci (NASDAQ: ABSI) director granted RSUs and stock options in equity awards - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 156 (M) |
| Held by Insiders | 1.4613e+008 (%) |
| Held by Institutions | 13 (%) |
| Shares Short | 35,090 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.1644e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -14 % |
| Return on Assets (ttm) | 346.9 % |
| Return on Equity (ttm) | -37.4 % |
| Qtrly Rev. Growth | 1.84e+006 % |
| Gross Profit (p.s.) | -34.37 |
| Sales Per Share | -26.85 |
| EBITDA (p.s.) | -3.43655e+007 |
| Qtrly Earnings Growth | -0.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -97 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.26 |
| Price to Cash Flow | 14.58 |
| Dividend | 0 |
| Forward Dividend | 3.223e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|